The pharmacokinetics and disposition of MK-0524, a Prosglandin D 2 receptor 1 antagonist, in rats, dogs and monkeys

Xenobiotica

Volumn 37, Issue 5, 2007, Pages 514-533

  Chang, S W ^a   Reddy, V ^a   Pereira, T ^a   Dean, B J ^a   Xia, Y Q ^a   Seto, C ^b   Franklin, R B ^a   Karanam, B V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Acyl glucuronide; Metabolism; MK 0524; Pharmacokinetics

Indexed keywords

MK 0524; PROSTAGLANDIN D 2 RECEPTOR 1 ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; CANNULATION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; MALE; MONKEY; NONHUMAN; RAT;

ANIMALS; BILE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG STABILITY; GLUCURONIDES; HALF-LIFE; HAPLORHINI; HUMANS; INDOLES; MALE; MASS SPECTROMETRY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

CANIS FAMILIARIS; RATTUS;

EID: 34249301403     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250601175565     Document Type: Article

References (14)

1. Cheng K, Wu T-J, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, et al. 2006. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences of the USA 103:6682-6687.
2. Dean B, Chang S, Elipe M, Xia Y-Q, Braun M, Soli E, Zhao Y, Franklin R & Karanam B. 2007. Drug Metabolism and Disposition 35:289-292.
3. Eklund B, Kaijser L, Nowak J, Wennmalm A. 1979. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17:821-830.
4. Gentile S, Rubba P, Persico M, Bronzino P, Marmo R, Faccenda F. 1985. Improvement of the nicotinic acid test in the diagnosis of Gilbert's syndrome by pretreatment with indomethacin. Hepatogastroenterology 32:267-269.
5. Iwaki M, Bischer A, Nguyen AC, McDonagh AF, Benet LZ. 1995. Stereoselective disposition of naproxen glucuronide in the rat. Drug Metabolism and Disposition 23:1099-1103.
6. Knopp RH. 1999. Drug treatment of lipid disorders. New England Journal of Medicine 341:498-511.
7. Kreiter PA, Colletti AE, Doss GA, Miller RR. 1994. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metabolism and Disposition 22:625-630.
8. Morrow JD, Awad JA, Oates JA, Roberts II LJ. 1992. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. Journal of Investigative Dermatology 98:812-815.
9. Nicoll-Griffith DA, Seto C, Aubin Y, Lévesque J-F, Chauret N, Day S, Silva JM, Trimble LA, Truchon JF, Berthelette C, Lachance N, Wang Z, Sturino C, Braun M, Zamboni R, Young RN. 2007. In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorganic and Medicinal Chemistry Letters 17(2):301-304.
10. Rubenfire M. 2004. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the impact of medical subspeciality on patient compliance to treatment (IMPACT) study. American Journal of Cardiology 94:306-311.
11. Shepherd J, Packard DJ, Patsch JR, Gotto Jr AM, Taunton OD. 1979. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoptotein A metabolism. Journal of Clinical Investigation 63:858-867.
12. 2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3, 4-tetrahydrocyclopenta [b]indol-3-yl]-acetic acid (MK-0524). Journal of Medicinal Chemistry 50(4):794-806.
13. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. 2006. On behalf of the Nautilus Study Group, 2006. Evaluation of safety and tolerability of prolonged-release nicotonic acid in a usual care setting. Current Medical Research and Opinion 22:417-425.
14. Zhao X-Q, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, Brown BG. 2004. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). American Journal of Cardiology 93:307-312.